


CLAIMS

1. Z isomer of the 3-[(3-{[4-(4-Morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II):




wherein the notation  means that the double bond is of configuration Z or E.

2. ~~Compound according to claim 1, which is the Z isomer of 3-[(3-{[4-(4-Morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate.~~
3. ~~2.~~ Compound according to claim 1 ~~or 2~~, characterised by its X-ray powder diffractogram by the Bragg's angles 2 theta (expressed in terms of °+0.2) 12.86; 15.13; 15.50; 17.70; 18.25; 18.71; 20.11; 21.46; 21.67; 21.89; 22.29; 22.58; 24.57; 25.82; 26.33.
4. ~~3.~~ Compound according to claim 1 ~~or 2~~, characterised by the following parameters obtained starting from the powder diffractogram carried out on a Panalytical Xpert-Pro MPD diffractometer (copper anticathode) in transmission mode with an angular range of 3-55° in terms of 2θ, a step of 0.017° and 35.5 s per step, which makes it possible to identify the following crystal parameters:
 - unit cell parameters: a = 15.0958(5) Å, b = 18.4586(6) Å, c = 8.8269(2) Å, β = 94.074(1)°, γ = 90°
 - space group: C 1 c 1 (9)
 - volume of unit cell: V_{unit cell} = 2453.37600 Å³.
5. ~~4.~~ Process for obtaining the compound of formula (II) according to claim 1, characterised in that there is used as starting material 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)-methyl]-1,3-thiazolidine-2,4-dione, which is dissolved in a binary system of solvent/water, to which from 1 to 2 molar equivalents of methanesulphonic acid are added, stirring until the methanesulphonate precipitates out, which is filtered off.
6. ~~5.~~ Process for obtaining the compound of formula (II) according to claim 1, characterised in that there is used as starting material 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)-methyl]-1,3-thiazolidine-2,4-dione hydrochloride, which is dissolved in a binary system of solvent/water, the pH of which is brought to 8 by adding a base, the salt formed is removed by filtration, and then the filtrate is heated and the methanesulphonic acid added, and the medium is stirred and cooled until the methanesulphonate precipitates out, which is filtered off.
7. ~~6.~~ Pharmaceutical composition comprising the compound of formula (II) that is the Z isomer of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3 dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate according to one of claims 1 to ~~4-3~~ in combination with one or more pharmaceutically acceptable excipients.

- ~~8. Pharmaceutical composition according to claim 7, characterised in that the compound of formula (II) is the Z isomer of 3-[(3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate.~~
9. 7. Pharmaceutical compositions according to claim 7 ~~or 8~~6 for use in the manufacture of medicaments for use in the treatment of cancers of the colon, breast, liver, kidneys, brain and oesophagus, melanomas, myelomas, ovarian cancers, non-small-cell lung cancers, small-cell lung cancers, prostate and pancreatic cancers, or sarcomas.
- ~~10. 8.~~ Association of a compound of formula (II) that is the Z isomer of 3-[(3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate according to any one of claims 1 to ~~4~~3 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.
- ~~11. Association according to claim 10, characterised in that the compound of formula (II) is the Z isomer of 3-[(3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate.~~
- ~~12. 9.~~ Use of an association according to claim ~~10 or 11~~8 in the manufacture of medicaments for use in the treatment of cancers.
- ~~13. Use of a compound of formula (II) according to any one of claims 1 to 4 in association with radiotherapy in the treatment of cancers.~~
14. Use according to claim 13, characterised in that the compound of formula (ii) is the Z isomer of 3-[(3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate.

CLAIMS

1. Z isomer of the 3-[(3-{[4-(4-Morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II):



2. Compound according to claim 1, characterised by its X-ray powder diffractogram by the Bragg's angles 2 theta (expressed in terms of °+0.2) 12.86; 15.13; 15.50; 17.70; 18.25; 18.71; 20.11; 21.46; 21.67; 21.89; 22.29; 22.58; 24.57; 25.82; 26.33.
3. Compound according to claim 1, characterised by the following parameters obtained starting from the powder diffractogram carried out on a Panalytical Xpert-Pro MPD diffractometer (copper anticathode) in transmission mode with an angular range of 3-55° in terms of 2θ, a step of 0.017° and 35.5 s per step, which makes it possible to identify the following crystal parameters:
 - unit cell parameters: $a = 15.0958(5) \text{ \AA}$, $b = 18.4586(6) \text{ \AA}$, $c = 8.8269(2) \text{ \AA}$, $\beta = 94.074(1)^\circ$, $\gamma = 90^\circ$
 - space group: C 1 c 1 (9)
 - volume of unit cell: $V_{\text{unit cell}} = 2453.37600 \text{ \AA}^3$.
4. Process for obtaining the compound of formula (II) according to claim 1, characterised in that there is used as starting material 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)-methyl]-1,3-thiazolidine-2,4-dione, which is dissolved in a binary system of solvent/water, to which from 1 to 2 molar equivalents of methanesulphonic acid are added, stirring until the methanesulphonate precipitates out, which is filtered off.
5. Process for obtaining the compound of formula (II) according to claim 1, characterised in that there is used as starting material 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)-methyl]-1,3-thiazolidine-2,4-dione hydrochloride, which is dissolved in a binary system of solvent/water, the pH of which is brought to 8 by adding a base, the salt formed is removed by filtration, and then the filtrate is heated and the methanesulphonic acid added, and the medium is stirred and cooled until the methanesulphonate precipitates out, which is filtered off.
6. Pharmaceutical composition comprising the compound of formula (II) that is the Z isomer of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate according to one of claims 1 to 3 in combination with one or more pharmaceutically acceptable excipients.
7. Pharmaceutical compositions according to claim 6 for use in the manufacture of medicaments for use in the treatment of cancers of the colon, breast, liver, kidneys, brain and oesophagus, melanomas, myelomas, ovarian cancers, non-small-cell lung cancers, small-cell lung cancers, prostate and pancreatic cancers, or sarcomas.

8. Association of a compound of formula (II) that is the Z isomer of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate according to any one of claims 1 to 3 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.
9. Use of an association according to claim 8 in the manufacture of medicaments for use in the treatment of cancers.